← Back to Clinical Trials
Recruiting NCT05433220

NCT05433220 PRagmatic Trial Of Messaging to Providers About Treatment of Heart Failure at Inova

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05433220
Status Recruiting
Phase
Sponsor Inova Health Care Services
Condition Heart Failure
Study Type INTERVENTIONAL
Enrollment 5,000 participants
Start Date 2022-08-25
Primary Completion 2027-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Best Practice Advisory using Electronic Health Record

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 5,000 participants in total. It began in 2022-08-25 with a primary completion date of 2027-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

A randomized, single-blind intervention trial to test the comparative effectiveness of an electronic health record best practice advisory system that informs clinicians of guideline-indicated and FDA-approved heart failure medications currently not prescribed to their patients with heart failure versus usual care (no alert and how things are done currently). The purpose of the alert is to stimulate appropriate medication prescription for patients with heart failure and a reduced ejection fraction. This will be done across outpatient Inova clinics and at the five Inova hospitals.

Eligibility Criteria

Inclusion Criteria: * Age\>18 Years * Seen by a Cardiologist in an Inova clinic or Inova hospital setting * Left Ventricular Ejection Fraction ≤40% Exclusion Criteria: * Opted out of EHR-based research * Hospice care * Already receiving maximally titrated doses of each of the four classes of evidence- based HFrEF medical therapy * Prior heart transplant

Contact & Investigator

Central Contact

Matthew G Dimond, BS

✉ matthew.dimond@inova.org

📞 7037762828

Principal Investigator

Mitchell Psotka, MD, PhD

PRINCIPAL INVESTIGATOR

Inova Health Care Services

Frequently Asked Questions

Who can join the NCT05433220 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05433220 currently recruiting?

Yes, NCT05433220 is actively recruiting participants. Contact the research team at matthew.dimond@inova.org for enrollment information.

Where is the NCT05433220 trial being conducted?

This trial is being conducted at Falls Church, United States.

Who is sponsoring the NCT05433220 clinical trial?

NCT05433220 is sponsored by Inova Health Care Services. The principal investigator is Mitchell Psotka, MD, PhD at Inova Health Care Services. The trial plans to enroll 5,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology